TY  - JOUR
AU  - Stajić, Ana
AU  - Maksić, Jelena
AU  - Maksić, Đoko
AU  - Forsdahl, Guro
AU  - Medenica, Mirjana
AU  - Jančić-Stojanović, Biljana
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3080
AB  - Aim: An ultra pressure liquid chromatography (UPLC)/MS/MS method for vancomycin and teicoplanin determination in human plasma was developed in accordance with analytical quality by design (AQbD) concept and fully validated. Materials & methods: Chromatographic separation was performed on ACQUITY UPLC C-18 charge surface hybrid (CSH) column (2.1 mm x 50 mm, 1.7 mu m particle size) in gradient mode and the mobile phase consisted of 0.1% formic acid in water and pure acetonitrile. The experimental design methodology was used for the definition of optimal chromatographic and protein precipitation conditions. Results: The linearity ranges were 0.05-10 mu g ml(-1) for vancomycin and 0.5-200 mu g ml(-1) for total teicoplanin. The relative standard deviations for precision estimation were below 15% and the accuracy was within 85-115% for all quality control levels. Conclusion: The method was utilized for glycopeptide antibiotics bioanalysis.
PB  - Future Sci Ltd, London
T2  - Bioanalysis
T1  - Analytical Quality by Design-based development and validation of ultra pressure liquid chromatography/MS/MS method for glycopeptide antibiotics determination in human plasma
VL  - 10
IS  - 22
SP  - 1861
EP  - 1876
DO  - 10.4155/bio-2018-0181
ER  - 

@article{
author = "Stajić, Ana and Maksić, Jelena and Maksić, Đoko and Forsdahl, Guro and Medenica, Mirjana and Jančić-Stojanović, Biljana",
year = "2018",
abstract = "Aim: An ultra pressure liquid chromatography (UPLC)/MS/MS method for vancomycin and teicoplanin determination in human plasma was developed in accordance with analytical quality by design (AQbD) concept and fully validated. Materials & methods: Chromatographic separation was performed on ACQUITY UPLC C-18 charge surface hybrid (CSH) column (2.1 mm x 50 mm, 1.7 mu m particle size) in gradient mode and the mobile phase consisted of 0.1% formic acid in water and pure acetonitrile. The experimental design methodology was used for the definition of optimal chromatographic and protein precipitation conditions. Results: The linearity ranges were 0.05-10 mu g ml(-1) for vancomycin and 0.5-200 mu g ml(-1) for total teicoplanin. The relative standard deviations for precision estimation were below 15% and the accuracy was within 85-115% for all quality control levels. Conclusion: The method was utilized for glycopeptide antibiotics bioanalysis.",
publisher = "Future Sci Ltd, London",
journal = "Bioanalysis",
title = "Analytical Quality by Design-based development and validation of ultra pressure liquid chromatography/MS/MS method for glycopeptide antibiotics determination in human plasma",
volume = "10",
number = "22",
pages = "1861-1876",
doi = "10.4155/bio-2018-0181"
}

Stajić, A., Maksić, J., Maksić, Đ., Forsdahl, G., Medenica, M.,& Jančić-Stojanović, B.. (2018). Analytical Quality by Design-based development and validation of ultra pressure liquid chromatography/MS/MS method for glycopeptide antibiotics determination in human plasma. in Bioanalysis
Future Sci Ltd, London., 10(22), 1861-1876.
https://doi.org/10.4155/bio-2018-0181

Stajić A, Maksić J, Maksić Đ, Forsdahl G, Medenica M, Jančić-Stojanović B. Analytical Quality by Design-based development and validation of ultra pressure liquid chromatography/MS/MS method for glycopeptide antibiotics determination in human plasma. in Bioanalysis. 2018;10(22):1861-1876.
doi:10.4155/bio-2018-0181 .

Stajić, Ana, Maksić, Jelena, Maksić, Đoko, Forsdahl, Guro, Medenica, Mirjana, Jančić-Stojanović, Biljana, "Analytical Quality by Design-based development and validation of ultra pressure liquid chromatography/MS/MS method for glycopeptide antibiotics determination in human plasma" in Bioanalysis, 10, no. 22 (2018):1861-1876,
https://doi.org/10.4155/bio-2018-0181 . .

TY  - JOUR
AU  - Forsdahl, Guro
AU  - Jančić-Stojanović, Biljana
AU  - Anđelković, Marija
AU  - Dikić, Nenad
AU  - Geisendorfer, Tomas
AU  - Jeitler, Veronika
AU  - Gmeiner, Gunter
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3044
AB  - Meldonium is a drug exhibiting cardioprotective and anti-ischemic effects. Due to its potential performance-enhancing benefit in sports, meldonium was added to the World Anti-Doping Agency list of prohibited substances in 2016. Since then, a high number of adverse analytical findings reported on meldonium has questioned meldonium's detection time in urine. Hence, the objective of the current study was to characterize the pharmacokinetic urinary excretion pattern of meldonium when administered as multiple intravenous injections. Three injections of 250 mg meldonium were given over a time period of five days to six healthy volunteers and urine samples were collected for eight months after the last injection of the drug. For the quantification of meldonium in urine, a liquid chromatography-tandem mass spectrometry method was fully validated according to the World Anti-Doping Agency guidelines in terms of specificity, matrix interferences, intra- and inter-day precision, accuracy, carry-over, robustness, linearity, limit of detection, and limit of quantification. The assay was successfully applied to the pharmacokinetic study. A three-compartment model was found to best describe the pharmacokinetics of meldonium with average alpha, beta, and gamma half-lives of 1.4 h, 9.4 h, and 655 h, respectively. The detection time in urine varied between 94 and 162 days.
PB  - Elsevier Science BV, Amsterdam
T2  - Journal of Pharmaceutical and Biomedical Analysis
T1  - Urinary excretion studies of meldonium after multidose parenteral application
VL  - 161
SP  - 289
EP  - 295
DO  - 10.1016/j.jpba.2018.08.053
ER  - 

@article{
author = "Forsdahl, Guro and Jančić-Stojanović, Biljana and Anđelković, Marija and Dikić, Nenad and Geisendorfer, Tomas and Jeitler, Veronika and Gmeiner, Gunter",
year = "2018",
abstract = "Meldonium is a drug exhibiting cardioprotective and anti-ischemic effects. Due to its potential performance-enhancing benefit in sports, meldonium was added to the World Anti-Doping Agency list of prohibited substances in 2016. Since then, a high number of adverse analytical findings reported on meldonium has questioned meldonium's detection time in urine. Hence, the objective of the current study was to characterize the pharmacokinetic urinary excretion pattern of meldonium when administered as multiple intravenous injections. Three injections of 250 mg meldonium were given over a time period of five days to six healthy volunteers and urine samples were collected for eight months after the last injection of the drug. For the quantification of meldonium in urine, a liquid chromatography-tandem mass spectrometry method was fully validated according to the World Anti-Doping Agency guidelines in terms of specificity, matrix interferences, intra- and inter-day precision, accuracy, carry-over, robustness, linearity, limit of detection, and limit of quantification. The assay was successfully applied to the pharmacokinetic study. A three-compartment model was found to best describe the pharmacokinetics of meldonium with average alpha, beta, and gamma half-lives of 1.4 h, 9.4 h, and 655 h, respectively. The detection time in urine varied between 94 and 162 days.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
title = "Urinary excretion studies of meldonium after multidose parenteral application",
volume = "161",
pages = "289-295",
doi = "10.1016/j.jpba.2018.08.053"
}

Forsdahl, G., Jančić-Stojanović, B., Anđelković, M., Dikić, N., Geisendorfer, T., Jeitler, V.,& Gmeiner, G.. (2018). Urinary excretion studies of meldonium after multidose parenteral application. in Journal of Pharmaceutical and Biomedical Analysis
Elsevier Science BV, Amsterdam., 161, 289-295.
https://doi.org/10.1016/j.jpba.2018.08.053

Forsdahl G, Jančić-Stojanović B, Anđelković M, Dikić N, Geisendorfer T, Jeitler V, Gmeiner G. Urinary excretion studies of meldonium after multidose parenteral application. in Journal of Pharmaceutical and Biomedical Analysis. 2018;161:289-295.
doi:10.1016/j.jpba.2018.08.053 .

Forsdahl, Guro, Jančić-Stojanović, Biljana, Anđelković, Marija, Dikić, Nenad, Geisendorfer, Tomas, Jeitler, Veronika, Gmeiner, Gunter, "Urinary excretion studies of meldonium after multidose parenteral application" in Journal of Pharmaceutical and Biomedical Analysis, 161 (2018):289-295,
https://doi.org/10.1016/j.jpba.2018.08.053 . .